View Older Stories View More Recent Stories

Oct 9, 2024 08:00AM Clene to Present at Upcoming October Conferences
Oct 1, 2024 04:00PM Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
Sep 30, 2024 08:30AM Clene (CLNN) Announces $7.3M Offering
Sep 30, 2024 08:30AM Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
Sep 3, 2024 08:00AM Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 6, 2024 08:02AM Clene (CLNN) Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
Aug 6, 2024 08:00AM Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
Jul 17, 2024 07:00AM Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Jul 12, 2024 10:34AM Clene to Present at the Emerging Growth Conference
Jul 11, 2024 09:00AM Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval
Jul 9, 2024 08:01AM Clene (CLNN) Announces 1:20 Reverse Share Split
Jul 9, 2024 08:00AM Clene Announces 1-for-20 Reverse Stock Split
Jun 24, 2024 08:00AM Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
Jun 21, 2024 07:10AM Clene (CLNN) Reports Prelim Data for CNM-Au8
Jun 21, 2024 07:09AM Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
Jun 18, 2024 07:00AM Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meetin
Jun 12, 2024 07:00AM Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
Jun 11, 2024 07:00AM Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
Jun 5, 2024 08:00AM Clene to Present at the Emerging Growth Conference
May 28, 2024 07:30AM Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
May 14, 2024 08:00AM Clene to Present at Upcoming May Conferences
Mar 15, 2024 08:00AM Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Mar 13, 2024 08:00AM Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Mar 7, 2024 08:00AM Clene to Present at the 36th Annual ROTH Conference
Feb 29, 2024 08:00AM Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
Feb 22, 2024 08:10AM Clene (CLNN) Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs
Feb 22, 2024 08:00AM Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Jan 8, 2024 07:00AM Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
Dec 21, 2023 07:02AM Clene (CLNN) Reports Reduction in Biomarker Plasma NfL Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Dec 21, 2023 07:01AM Clene (CLNN) Provides Update on ALS Clinical Development Meeting With FDA
Dec 21, 2023 07:00AM Clene Provides Update on ALS Clinical Development Meeting With FDA
Dec 21, 2023 07:00AM Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Dec 14, 2023 08:38AM Clene (CLNN) Reports Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Dec 14, 2023 08:36AM Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Nov 7, 2023 08:00AM Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
Oct 5, 2023 10:01AM Clene (CLNN)Announces National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS
Oct 5, 2023 10:00AM National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Sep 28, 2023 08:00AM Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Sep 25, 2023 04:00PM Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
Sep 25, 2023 07:00AM Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Aug 30, 2023 08:20AM Clene to Present at Upcoming September Conferences
Aug 29, 2023 07:00AM Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
Aug 14, 2023 08:00AM Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Aug 2, 2023 07:00AM Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
Jun 26, 2023 08:00AM Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Jun 21, 2023 09:20AM Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
Jun 16, 2023 08:00AM Clene (CLNN) Prices 50M Share Offering at $0.80/sh
Jun 16, 2023 08:00AM Clene Announces Pricing of $40 Million Public Offering
Jun 15, 2023 04:39PM Clene (CLNN) Announces Launch of Proposed Public Offering
Jun 15, 2023 04:38PM Clene Announces Launch of Proposed Public Offering
View More Recent Stories View Older Stories